Viridian Therapeutics, Inc.\DE (VRDN) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to -$35.1 million.
- Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders rose 5417.68% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 1774.81%. This contributed to the annual value of -$269.9 million for FY2024, which is 1355.09% down from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders is -$35.1 million, which was up 5417.68% from -$100.7 million recorded in Q2 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders registered a high of -$14.0 million during Q3 2021, and its lowest value of -$100.7 million during Q2 2025.
- In the last 5 years, Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders had a median value of -$47.7 million in 2023 and averaged -$49.4 million.
- Within the past 5 years, the most significant YoY rise in Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders was 6810.08% (2021), while the steepest drop was 17916.08% (2021).
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Net Income towards Common Stockholders stood at -$28.9 million in 2021, then plummeted by 58.17% to -$45.8 million in 2022, then crashed by 46.03% to -$66.9 million in 2023, then fell by 19.33% to -$79.8 million in 2024, then soared by 56.07% to -$35.1 million in 2025.
- Its last three reported values are -$35.1 million in Q3 2025, -$100.7 million for Q2 2025, and -$86.9 million during Q1 2025.